Drug intelligence / Profile preview

ReT01 ACT

Development stage: Phase 1
Lead developer: Aeonvital Biomedicine
Administration: Injection

Overview

ReT01 ACT is an investigational therapy being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and preliminary efficacy are being evaluated in patients with advanced solid tumors. The specific mechanism of action and modality have not been disclosed publicly. The drug is administered via injection and has not received regulatory approval in any country as of now. Development is led by Aeonvital Biomedicine, with involvement from Beijing Anweisen Biomedicine.

Beyond the preview

Go deeper on ReT01 ACT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReT01 ACT.

Explore the full profile